ArticleScientific reports2026
Functional characterization of a type I-F1 CRISPR-cas system from the clinical isolate Shewanella xiamenensis Sh95 reveals constitutive activity and plasmid-curing capability.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
CRISPR-Cas are prokaryotic adaptive immunity defense systems that provide protection through RNA-guided recruited nucleases effectors.Despite the vast diversity in which CRISPR-Cas systems naturally exist, the single effectors from Class 2 were the most studied as genetic engineering tools. Later, the endogenous reprogramming of type I CRISPR-Cas systems showed promising results in diverse bacteria. However, the features and functions of the subtype I-F1 from Shewanella spp. members remain poorly characterized. Here, we report the analysis of the genetic context and activity of a type I-F1 CRISPR-Cas system within the species from the clinical isolate Shewanella xiamenensis Sh95 (SxCRISPR-Cas3). We show that this system transcribes constitutively and contains an internal promoter within cas3f open reading frame. Using endogenous reprogramming assays with synthetic mini CRISPR arrays, we demonstrate that the system is functionally active producing target plasmid interference and plasmid curing. Together, these results represent a simple methodology for obtaining colonies of S. xiamenensis Sh95 cured from the target plasmid and lay the foundation to the future exploration of SxCRISPR-Cas3 as a programmable interference tool.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.